Cleary Gottlieb represented GlaxoSmithKline plc and GlaxoSmithKline Capital Inc., a finance subsidiary, in the offering by GlaxoSmithKline Capital Inc. of $1.25 billion of 0.700% notes due 2016, $1.25 billion of 2.800% notes due 2023 and $0.5 billion of 4.200% notes due 2043. The notes, issued under a shelf registration statement and wholly and unconditionally guaranteed by GlaxoSmithKline plc, have been listed on the New York Stock Exchange. The offering closed on March 18.
GlaxoSmithKline is a major global healthcare company engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer health-related products.
